Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

Articles

HR+ MBC: Prognostic Factors and Treatment Planning

October 11th 2021

Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.

Identifying PIK3CA Mutations in HR+ HER2- MBC

October 11th 2021

Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.

Monitoring Patients for Interstitial Lung Disease

October 1st 2021

Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.

Identifying Risk Factors for Interstitial Lung Disease

October 1st 2021

A brief review of the full spectrum of risk factors that impact the likelihood of interstitial lung disease.

Identifying ILD: Symptomology and Work-Up

September 24th 2021

Comprehensive insight on the symptomology of interstitial lung disease, followed by tools and methods that can aid in accurate diagnosis.

An Overview of Interstitial Lung Disease

September 24th 2021

Joyce A. O’Shaughnessy, MD, provides an overview of interstitial lung disease, considering both causes and possible risk factors.

Multidisciplinary Care in Breast Cancer: Take-Home Messages

September 22nd 2021

Take-home messages regarding the optimal identification and management of ILD in breast cancer through the lens of multidisciplinary care.

Practical Considerations for Identifying and Managing ILD in Breast Cancer

September 22nd 2021

Drawing from personal experience, experts provide practical advice on identifying and treating interstitial lung disease in patients with breast cancer during the era of COVID-19.

Optimal Management of ILD in Patients With Breast Cancer

September 15th 2021

Shared insight on the optimal management of patients who develop interstitial lung disease while receiving therapy for breast cancer.

Breast Cancer Management: Monitoring Patients for ILD

September 15th 2021

In light of breast cancer therapies with the potential to cause interstitial lung disease, experts consider important patient risk factors and best monitoring practices.

Multidisciplinary Care for a Patient With Metastatic HER2+ Breast Cancer

September 8th 2021

An overview of optimal multidisciplinary care for a patient who presents with HER2+ metastatic breast cancer.

Challenges in the Multidisciplinary Management of Breast Cancer

September 8th 2021

Key opinion leaders highlight the challenges inherent in using multidisciplinary care to manage breast cancer, particularly when a patient is seen at multiple institutions.

Multidisciplinary Care in BC: How Best to Communicate Patient Information

September 1st 2021

Focusing on the value of electronic systems and tumor boards, experts detail how best to communicate across disciplines in the management of breast cancer.

Difference in Breast Cancer Outcomes With Multidisciplinary Care

September 1st 2021

Shared insight on how nuanced multidisciplinary care can positively impact outcomes when treating a patient with breast cancer.

Managing Breast Cancer: Collaboration Throughout the Treatment Journey

August 25th 2021

Comprehensive details on how multidisciplinary care is applied during a patient’s treatment journey, with a focus on pulmonology and critical care.

Managing Breast Cancer: Who’s Involved in Multidisciplinary Care?

August 25th 2021

Experts reflect on the importance of multidisciplinary care and outline the many disciplines involved in diagnosing and treating breast cancer.

Future Directions for Treatment of TNBC

October 23rd 2020

Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events

October 23rd 2020

Phase 3 ASCENT Trial in mTNBC

October 23rd 2020

Sequencing Therapies for mTNBC

October 23rd 2020